MADDEN SECURITIES Corp grew its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,164 shares of the biopharmaceutical company’s stock after buying an additional 1,860 shares during the quarter. MADDEN SECURITIES Corp’s holdings in Pfizer were worth $263,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. increased its stake in shares of Pfizer by 0.6% in the first quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock valued at $18,171,704,000 after buying an additional 2,516,132 shares in the last quarter. Wellington Management Group LLP increased its position in Pfizer by 9.8% in the first quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock worth $8,932,423,000 after purchasing an additional 19,602,359 shares during the period. Moneta Group Investment Advisors LLC increased its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Geode Capital Management LLC increased its position in Pfizer by 0.5% in the first quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock worth $4,472,433,000 after purchasing an additional 577,201 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Pfizer by 14.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock worth $3,408,836,000 after purchasing an additional 10,560,702 shares during the period. 68.05% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Trading Down 0.4 %
Shares of Pfizer stock opened at $34.03 on Friday. Pfizer Inc. has a 12-month low of $33.54 and a 12-month high of $54.93. The stock has a market cap of $192.13 billion, a P/E ratio of 9.05, a P/E/G ratio of 1.14 and a beta of 0.59. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $35.83 and its 200-day moving average is $38.04.
Pfizer Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.82%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio is currently 43.62%.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on PFE. JPMorgan Chase & Co. lowered their price objective on Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a research report on Monday, July 17th. Morgan Stanley lowered their price objective on Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 2nd. HSBC started coverage on Pfizer in a research report on Friday, July 14th. They set a “buy” rating and a $50.00 target price for the company. BMO Capital Markets decreased their target price on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a research report on Wednesday, August 2nd. Finally, Jefferies Financial Group decreased their target price on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Twelve investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $46.35.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- Stock Analyst Ratings and Canadian Analyst Ratings
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 9/11 – 9/15
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.